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We describe 4 cases of Legionella pneumophila
serogroup 13–associated pneumonia. These cases origi-
nate from a broad geographic range that includes Scotland,
Australia, and New Zealand. L. pneumophila serogroup 13
pneumonia has a clinically diverse spectrum that ranges
from relatively mild, community-acquired pneumonia to
potentially fatal severe pneumonia with multisystem organ
failure. All cases were confirmed by culture and direct fluo-
rescent antibody staining or indirect immunofluorescent
antibody tests. Proven or putative sources of L. pneumophi-
la serogroup 13 infections in 2 patients included a contami-
nated whirlpool spa filter and river water. An environmental
source was not found in the remaining 2 cases; environ-
mental cultures yielded only other L. pneumophila
serogroups or nonpneumophila Legionella species. We
describe the clinical and laboratory features of L. pneu-
mophila serogroup 13 infections. L. pneumophila serogroup
13 pneumonia is rarely reported, but it may be an underrec-
ognized pathogenic serogroup of L. pneumophila. 
L
egionella species are relatively common causes of
pneumonia (1). Legionella pneumophila is the most
common pathogenic species, with 15 serogroups
described. L. pneumophila serogroup 1 accounts for most
culture-confirmed cases of legionellosis; non–serogroup 1
L. pneumophila causes only ≈7% of legionellosis cases (2).
Legionellae are widely distributed in the environment,
including in lakes, rivers, creeks (1,3), and artificial aquat-
ic habitats such as potable-water supplies (1,3); amebae
are the natural hosts in the environment (4).
L. pneumophila serogroup 13 was first described as a
new pathogenic serogroup of L. pneumophila in 1987 (5),
but a detailed clinical account of these cases was not
included in the initial report. L. pneumophila serogroup 13
is rarely reported in humans; it accounted for 2 (0.4%) of
508 isolates from a recent international survey of culture-
confirmed legionellosis (2). Furthermore, a recent
European study of 1,335 unrelated clinical isolates yielded
only 2 isolates of L. pneumophila serogroup 13 (6). We are
unaware of published reports of L. pneumophila serogroup
13 infections in which the epidemiology and the clinical
spectrum are outlined. We therefore report 4 cases of L.
pneumophila serogroup 13 infections to describe in detail
these aspects of this uncommon human pathogen.
The Cases
Case 1
A27-year-old woman was admitted to an intensive care
unit in Glasgow, Scotland, after she had nearly drowned in
estuarine water. On admission, her vital signs were as fol-
lows: core body temperature 32.8°C, pulse 92 beats per
min, blood pressure 90/65 mm Hg, respiratory rate 28
breaths per min, and Glasgow Coma Scale score 13/15.
Arterial blood gas analysis on 100% oxygen showed par-
tial arterial oxygen pressure (PaO2) 46 mm Hg (reference
range [RR] >90 mm Hg), PaCO2 48 mm Hg (RR 25–35
mm Hg), and bicarbonate 16.2 mmol/L (RR 24–30
mmol/L). Her blood biochemistry showed hyponatremia
and hypokalemia. Chest radiograph showed bilateral con-
solidation. She was intubated, given ventilatory assistance,
and actively rewarmed; inotropes were administered, and
empiric intravenous cefotaxime and metronidazole were
given. With the patient’s further clinical deterioration,
intravenous vancomycin replaced metronidazole on day 6.
On day 7, high-dose methylprednisolone was adminis-
tered for worsening respiratory function and chest
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drome. Given the patient’s poor clinical response, on day
14, intravenous clarithromycin and gentamicin were given,
with intravenous ciprofloxacin added 24 hours later. Acute
renal failure required hemofiltration, and respiratory func-
tion deteriorated further on day 15, despite prone ventila-
tion and nitric oxide therapy. On day 18, she died of
refractory hypoxemia and multisystem organ failure. Atra-
cheal aspirate collected on day 14 plus postmortem lung
tissue samples subsequently yielded colonies of a
Legionella species on buffered-charcoal yeast extract
(BCYE) agar (Oxoid Ltd., Basingstoke, England). L. pneu-
mophila  serogroup 13 infection was diagnosed by mip
gene sequencing of the isolate, which demonstrated 99%
homology with the type strain of L. pneumophila
serogroup 13 (GenBank accession no. AF022327).
Seroconversion was demonstrated retrospectively by indi-
rect immunofluorescent antibody (IFA) against monoclon-
al L. pneumophila serogroup 13 antisera, with a titer rise
from <1:32 on admission to 1:512 on day 12. Domestic or
nosocomial sources of legionellosis were not sought.
Nevertheless, several months later, estuarine water sam-
ples were taken near the site of immersion; cultures were
negative for Legionella spp.
Case 2
A 51-year-old man who was undergoing induction
chemotherapy for acute myeloid leukemia at Royal Perth
Hospital, Australia, was initially given regular and extend-
ed periods of home leave in the first week after chemother-
apy. However, on day 12 neutropenic typhlitis developed,
and a right hemicolectomy was performed. This procedure
was followed the next day by the onset of dyspnea, hypox-
emia, nonproductive cough, and persistent fever. Chest
radiograph showed left lower lobe consolidation, and
meropenem with teicoplanin was administered empirical-
ly. He initially remained profoundly neutropenic (neu-
trophil count <0.1 × 109/L [RR 2.0–7.5 × 109/L]). Two
days later his hypoxemia and chest radiograph results had
worsened, and trimethoprim-sulfamethoxazole, ampho-
tericin B, and roxithromycin were administered. On day
18, he had extensive consolidation that involved most of
both lung fields, and his neutrophil count had increased to
2.46 × 109/L.
Bronchoscopic samples collected on day 19 were posi-
tive for Legionella species antigen by direct immunofluo-
rescent monoclonal antibody stain (DFA) (Genetic
Systems, Seattle, WA, USA), but results of his Legionella
urinary antigen test (Binax Now, Binax, Portland, ME,
USA) were negative. Four days later, Legionella species
were isolated on BCYE agar (Oxoid Ltd.) and confirmed
by DFA(Legionella Poly-ID Test Kit, Remel, Lenexa, KS,
USA) and also by L. pneumophila serogroup 2-14 (LP-2-
14) antisera (MarDx Diagnostics, Scotch Plains, NJ,
USA). Environmental samples were taken of both hospital
and home water. All isolates were then referred to the
Australian Legionella Reference Laboratory, Institute of
Medical and Veterinary Science, Adelaide, Australia, for
typing. Typing confirmed that the clinical isolate was L.
pneumophila serogroup 13, both by monoclonal antisera
(MarDx Diagnostics) and mip gene sequencing. Hospital
water samples yielded L. pneumophila serogroup 10 from
both a hand basin cold-water outlet in the patient’s room
and a cold-water drinking fountain on an adjacent ward.
Restriction fragment length polymorphism (RFLP) and
pulsed-field gel electrophoresis (PFGE) typing confirmed
that the clinical and environmental isolates were genotyp-
ically distinct. The patient was then given intravenous
erythromycin followed by oral ciprofloxacin for 3 weeks;
subsequently, he made a slow but complete recovery.
Testing the patient’s home potable water supply yielded
only L. feeleii.
Case 3
A 48-year-old, previously healthy man was admitted to
the hospital in Christchurch, New Zealand, with a 6-day
history of increasing dyspnea and a 4-day history of watery
diarrhea. He also complained of a dry cough, myalgia, loss
of appetite, and poor fluid intake. He appeared flushed and
unwell and had dry mucous membranes. His vital signs
were the following: temperature 39ºC, pulse rate 103 beats
per min, blood pressure 154/83 mm Hg, respiratory rate 22
breaths per min, and oxygen saturation 94% on room air.
His leukocyte count was 6.1 × 109/L (RR 4.0–10 × 109/L),
and his serum sodium and potassium levels were 130
mmol/L (RR 136–146 mmol/L) and 3.3 mmol/L (RR
3.5–5.0 mmol/L), respectively. Liver biochemistry was
abnormal. His C-reactive protein (CRP) was >220 mg/L
(RR<10 mg/L). Chest radiographs showed pneumonia
with segmental consolidation of the lingula and left lower
lobe.
The patient’s temperature continued to increase to
39.4ºC and returned to normal only after 8 days, despite
prompt initiation of intravenous amoxicillin and clar-
ithromycin. Liver biochemistry initially deteriorated,
peaking on day 6, thereafter slowly returning to normal
when the patient was discharged 11 days after admission.
After 6 days of culture on BCYE agar (Oxoid Ltd.),
Legionella spp. were isolated from sputum collected on the
day after admission. The isolate was typed by
Environmental Science and Research Limited (ESR),
Communicable Diseases Group Laboratory Services,
Porirua, Wellington, New Zealand. A strong positive reac-
tion was seen to polyvalent antisera for L. pneumophila
serogroups 1–14 (Monoclonal Technologies Inc.,
Alpharetta, GA, USA). Monoclonal antisera (Monoclonal
RESEARCH
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Legionella strain 82A3105 (CDC 1425-CA-H; ATCC
43736), which identified the isolate as L. pneumophila
serogroup 13 (David Harte, pers. comm.).
Public health service investigation of the patient’s
home yielded L. pneumophila serogroup 13 from the filter
of an outdoor whirlpool spa. The patient recalled cleaning
this filter several days before falling ill. One month later
the patient had made a good recovery, although he was eas-
ily fatigued.
Case 4
A 56-year-old man was admitted to the hospital in
Christchurch, New Zealand, with a 1-week illness charac-
terized by myalgia, nausea, sweats, and chills but no respi-
ratory symptoms. He was a nonsmoker with negligible
alcohol intake; however, his past history included aortic
dissection requiring aortic valve replacement.
On admission he was afebrile, blood pressure was
112/66 mm Hg, and his respiratory rate was 16 breaths per
min. His chest was clear to auscultation, but his oxygen
saturation was 91% on room air, and chest radiograph
showed patchy bibasal consolidation. Leukocyte count and
serum sodium level were both normal, but his CRP was
elevated to 176 mg/L (RR<10 mg/L). Liver biochemistry
was slightly abnormal.
He was treated empirically for possible prosthetic valve
endocarditis with intravenous penicillin and gentamicin.
On the day after admission, he had productive cough and
sharp, left-sided chest pains; a temperature of 39ºC ensued.
Examination showed left basal dullness with bibasal
crackles and left basal bronchial breathing. However, he
improved rapidly without specific antimicrobial therapy
for legionellosis and was discharged 5 days later.
Asputum sample collected on day 2 yielded Legionella
species after 9 days of incubation on BYCE agar. With the
abovementioned methods, ESR typed the isolate as L.
pneumophila serogroup 13. Extensive investigations by
the local public health services yielded L. micdadei from
spa whirlpool water where the patient regularly swam.
Discussion
The patients we report had typical signs and symptoms
of Legionella pneumonia, including headache, anorexia,
dry cough, and fever, often with hyponatremia and abnor-
mal results of liver function tests (7). Patients had hypox-
emia, and disease often involved multiple lobes or both
lungs on chest radiograph (7). However, these patients
generally had minimal preexisting illnesses, apart from the
patient with acute myeloid leukemia who was undergoing
chemotherapy. The outcome for 3 of our patients was pos-
itive, including the patient with an underlying hematolog-
ic malignancy and neutropenia; legionellosis is often
associated with a markedly elevated death rate in these
cases (3,7,8). The patient who died was severely ill after
nearly drowning and had aspiration pneumonitis.
Moreover, specific therapy that was effective against
legionellosis was not started until 14 days after the putative
infection; delay in administering appropriate therapy is
known to adversely affect outcome (7,9).
L. pneumophila is responsible for ≈90% of infections
caused by members of the family Legionellaceae (1,3,7).
L. pneumophila serogroups 1, 3, 4, and 6 cause most
human infections (1,3,7). An international survey found
that of 15 serogroups of L. pneumophila, 79% of all cul-
ture- or urine antigen–confirmed infections were caused
by L. pneumophila serogroup 1 (8). Legionellae are fastid-
ious organisms that are not readily recovered from routine
diagnostic media; indeed, an American College of
Pathologists’ survey indicates that 32% of clinical micro-
biology laboratories could not grow a pure culture of L.
pneumophila (10). All of our isolates grew only on special-
ized media. Failure to diagnose legionellosis in many hos-
pital microbiology laboratories is generally due to a
limited availability of specialized media and expertise in
the culture of legionellae.
In the United States, from 1980–1998, clinicians have
increasingly relied on urinary antigen tests to diagnose
legionellosis. Use of these methods has led to an increase
in L. pneumophila serogroup 1 diagnoses from 0% to 69%,
with a corresponding decreased frequency of serogroups
other than 1 from 38% to 4% (11). Urinary antigen tests do
not reliably diagnose non–serogroup 1 L. pneumophila
infections (12,13), as illustrated by Benson et al., who
found sensitivities of 35% (Binax EIA) and 46% (Biotest-
EIA), respectively. However, no isolates of L. pneumophi-
la serogroup 13 were included in their evaluation (12),
although as illustrated by 2 of our cases, urinary antigen
assays will not likely diagnose this specific serogroup in
most cases. Furthermore, in the United States, surveillance
systems have found that diagnosis of legionellosis by cul-
ture, DFA, and serologic testing (IFA) decreased signifi-
cantly from 1980 to 1998 (11). Nevertheless, in case 2, the
DFA of bronchoalveolar lavage fluid was positive to poly-
valent antisera. Also in case 1, IFA serology showed sero-
conversion to L. pneumophila serogroup 13–specific
antigen. However, serologic diagnosis of Legionella infec-
tion has only been fully validated for L. pneumophila
serogroup 1 (14). Thus, the increasing reliance on noncul-
ture-based tests as the sole methods of diagnosing
legionellosis is a cause for concern, given the variable util-
ity of these assays.
In most cases, L. pneumophila pneumonia is attributed
to inhaling contaminated aerosols produced by cooling
towers, showers, and nebulizers (1,3,7). Aspiration is also
a possible mechanism of transmission (15,16). The source
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Legionellosis from Legionella pneumophila Serogroup 13and reservoir of L. pneumophila are generally not identi-
fied in sporadic legionellosis (17,18). However, in case 3,
the infection was linked epidemiologically and microbio-
logically with a contaminated spa whirlpool filter.
Although legionellosis is well described in association
with spa whirlpools (19,20), we are unaware of any previ-
ously reported cases of L. pneumophila serogroup 13
infections linked to spa whirlpools. Additionally, aspirat-
ing water and nearly drowning has a rare but well-recog-
nized association with L. pneumophila pneumonia
(21–23), although we are unaware of any previously
reported cases of L. pneumophila serogroup 13 pneumonia
after a person’s nearly drowning. For the remaining 2
cases, despite extensive environmental sampling, a source
or reservoir of infection was not established. In case 2,
whether the infection was nosocomial is unclear, given that
the patient had had extended periods of home leave.
Despite isolation of L. micdadei from a spa whirlpool
where patient 4 regularly swam, investigations failed to
find L. pneumophila serogroup 13. Serologic diagnosis of
L. pneumophila serogroup 13 pneumonia has been occa-
sionally reported from New Zealand and Australia,
although clinical data from these cases are unreported.
Recovery of environmental isolates mainly from soil and
water is also reported in this region (24–26).
Serotyping, serogrouping, typing, and subtyping
legionellae are technically challenging. Both phenotypic
and genotypic analyses of L. pneumophila are required to
reliably epidemiologically link patient and environmental
isolates. Phenotypic or genotypic studies in higher refer-
ence laboratories were performed on our isolates, thereby
reliably confirming their identity as L. pneumophila
serogroup 13. Epidemiologic studies to identify possible
sources of legionellosis require careful investigation,
including sensitive and discriminatory subtyping tech-
niques to identify similarities and differences between pos-
sibly related strains. Methods reported include various
panels of monoclonal antibodies, plasmid analysis, RFLPs,
ribotyping, macrorestriction enzyme digestion followed by
PFGE, and mip gene sequencing (27). Recently, Fry et al.
have suggested that amplified fragment length polymor-
phism typing may be the best method for investigating the
epidemiology of travel-related legionellosis (28). Newer
typing techniques for legionellosis include multilocus
sequencing typing and DNA chip technologies (29).
In summary, we describe for the first time in detail the
clinical and laboratory features of L. pneumophila
serogroup 13 infections. L. pneumophila serogroup 13 is a
rare but perhaps underrecognized pathogenic L. pneu-
mophila serogroup. Although the organism was first
reported in the United States (5), its global distribution is
highlighted here. We found that this organism produces a
broad spectrum of clinical disease, from relatively mild
disease to severe, potentially fatal pneumonia. Finally, this
report emphasizes that culture for Legionella species
remains important if the prevalence and incidence of
legionellosis are to be reliably and fully appreciated. 
Acknowledgments
We thank Bill Abraham and Diane Lindsay for performing
serologic typing and sequencing analysis of the L. pneumophila
serogroup 13 isolate from case 1; the Australian Legionella
Reference Laboratory staff for typing the clinical and environ-
mental isolates relating to case 2; Roslyn Podmore and her team
from Canterbury Health Laboratories, who isolated Legionella
species from the clinical specimens of patients with cases 3 and
4; and Paul Chadwick for reviewing the manuscript.
Dr B. Faris is consultant microbiologist in the Department
of Microbiology, Trafford General Hospital. His main research
interests are foot infections in patients with diabetes, intravenous
antimicrobial home therapy, and multidrug-resistant organisms.
References
1. Fields BS, Benson RF, Besser RE. Legionella and Legionnaires’ dis-
ease: 25 years of investigation. Clin Microbiol Rev. 2002;15:506–26.
2. Yu VL, Plouffe JF, Castellani-Pastoris M, Stout JE, Schousboe M,
Widmer A, et al. Distribution of Legionella species and serogroups
isolated by culture in patients with sporadic community-acquired
legionellosis: an international collaborative survey. J Infect Dis.
2002;186:127–8.
3. Stout JE, Rihs JD, Yu VL. Legionella. In: Murray PR, Baron EJ,
Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of clinical
microbiology. 8th ed. Washington: ASM Press; 2003. p. 809–23.
4. Adeleke A, Pruckler J, Benson R, Rowbotham T, Halablab M, Fields
B. Legionella-like amebal pathogens—phylogenetic status and possi-
ble role in respiratory disease. Emerg Infect Dis. 1996;2:225–30.
5. Lindquist DS, Nygaard G, Thacker WL, Benson RF, Brenner DJ,
Wilkinson HW. Thirteenth serogroup of Legionella pneumophila iso-
lated from patients with pneumonia. J Clin Microbiol.
1988;26:586–7.
6. Helbig JH, Bernander S, Castellani-Pastoris M, Etienne J, Gaia V,
Lauwers S, et al. Pan-European study on culture-proven
Legionnaires’ disease: distribution of Legionella pneumophila
serogroups and monoclonal subgroups. Eur J Clin Microbiol Infect
Dis. 2002;21:710–6.
7. Edelstein PH, Cianciotto NP. Legionella. In: Mandell GL, Bennett JE,
Dolin R, editors. Principles and practice of infectious diseases. 6th ed.
Philadelphia: Churchill Livingstone; 2004. p. 2711–24.
8. Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires’
disease: risk factors for morbidity and mortality. Arch Intern Med.
1994;154:2417–22.
9. Heath CH, Grove DI, Looke DF. Delay in appropriate therapy for
Legionella pneumonia is associated with increased mortality. Eur J
Clin Microbiol Infect Dis. 1996;15:286–90.
10. Edelstein PH. Legionnaires’disease. Clin Infect Dis. 1993;16:741–9.
11. Benin AL, Benson RF, Besser RE. Trends in Legionnaires’ disease,
1980–1998: declining mortality and new patterns of diagnosis. Clin
Infect Dis. 2002;35:1039–46.
12. Benson RF, Tang WT, Fields BS. Evaluation of the Binax and Biotest
urinary antigen kits for the detection of Legionnaires’ disease due to
multiple serogroups and species of Legionella. J Clin Microbiol.
2000;38:2763–5.
RESEARCH
1408 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 9, September 2005Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 9, September 2005 1409
13. Horn J. Comparison of non-serogroup 1 detection by Biotest and
Binax Legionella urinary antigen enzyme immunoassays. In: Marre
R, Abu Kwaik Y, Bartlett C, Cianciotto NP, Fields BS, Frosch M, et
al., editors. Legionella. Washington: ASM Press; 2002. p. 207–10.
14. Wilkinson HW, Cruce DD, Broome CV. Validation of Legionella
pneumophila indirect immunofluorescent antibody with epidemic
sera. J Clin Microbiol. 1981;13:139–46.
15. Muder RR, Yu VL, Woo A. Mode of transmission of Legionella pneu-
mophila: a critical review. Arch Intern Med. 1986;146:1607–12.
16. Yu VL. Could aspiration be the major mode of transmission for
Legionella? Am J Med. 1993;95:13–5.
17. England AC III, Fraser DW, Plikaytes BD, Tsai TF, Storch G, Broome
CV. Sporadic legionellosis in the United States: the first thousand
cases. Ann Intern Med. 1981;94:164–70.
18. Fiore AE, Nuorti JP, Levine OS, Marx A, Weltman AC, Yeager S, et
al. Epidemic Legionnaires’ disease two decades later: old sources,
new diagnostic methods. Clin Infect Dis. 1998;26:426–33.
19. Centers for Disease Control and Prevention. Surveillance data from
public spa inspections—United States, May–September 2002.
MMWR Morb Mortal Wkly Rep. 2004;53:553–5.
20. Den Boer JW, Yzerman EPF, Schellekens J, Lettinga KD, Boshuizen
HC, Van Steenbergen JE, et al. A large outbreak of Legionnaires’at a
flower show, the Netherlands, 1999. Emerg Infect Dis. 2002;8:37–43.
21. Farrant JM, Drury AE, Thompson RP. Legionnaires’ disease follow-
ing immersion in river water. Lancet. 1988;2:460.
22. Nagai T, Sobajima H, Iwasa M, Tsuzuki T, Kura F, Amemura-
Maekawa J, et al. Neonatal sudden death due to Legionella pneu-
mophila pneumonia associated with water birth in a domestic spa
bath. J Clin Microbiol. 2003;41:2227–9.
23. Franzin L, Scolfaro C, Cabodi D, Valera M, Tovo PA. Legionella
pneumonia in a newborn after water birth: a new mode of transmis-
sion. Clin Infect Dis. 2001;33:e103–4.
24. Institute of Environmental Science and Research Limited.
Communicable Diseases Group Laboratory Services, Porirua (New
Zealand). LabLink. 1998;5:31.
25. Institute of Environmental Science and Research Limited.
Communicable Diseases Group Laboratory Services, Porirua (New
Zealand). LabLink. 1999;6:3.
26. Institute of Environmental Science and Research Limited.
Communicable Diseases Group Laboratory Services, Porirua (New
Zealand). LabLink. 2000;8:4.
27. Ratcliff RM, Lanser JA, Manning PA, Heuzenroeder MW. Sequence-
based classification scheme for the genus Legionella targeting the
mip gene. J Clin Microbiol. 1998;36:1560–7.
28. Fry NK, Bangsborg JM, Bernarder S, Etienne J, Forsblorn B, Gaia V,
et al. Assessment of intercenter reproducibility and concordance of
Legionella pneumophila serogroup 1 genotyping by amplified frag-
ment length polymorphisms. Eur J Clin Microbiol Infect Dis.
2000;19:773–80.
29. Gaia V, Peduzzi R. Multi-locus sequence typing for characterization
of Legionella pneumophila serogroup 1 isolates. In: Marre R, Abu
Kwaik Y, Bartlett C, Cianciotto NP, Fields BS, Frosch M, et al., edi-
tors. Legionella. Washington: ASM Press; 2002. p. 251–3.
Address for correspondence: Barzo Faris, Department of Microbiology,
Trafford General Hospital, Moorside Rd, Davyhulme, Manchester M41
5SL, United Kingdom; fax: 44-161-746-8545; email: kingella@
yahoo.co.uk
Legionellosis from Legionella pneumophila Serogroup 13
www.cdc.gov/ncidod/EID/cover_images/covers.htm